A multicenter, open-label study to evaluate the sensitivity and specificity of inhaled methacholine in bronchial provocation test

Inclusion Criteria:

Patients who meet all the following inclusion criteria can be included in this trial:

• 1 Adults 65 years of age ≥ 18 years of age, male or female;
• 2 Normal or abnormal pulmonary function test without clinical significance (FEV1 ≥ 70% predicted);
• 3 Voluntary, signed informed consent, good compliance, can cooperate with the trial observation.

Patients with asthma:

• 4 Clinical diagnosis of asthma patients;
• 5 Patients who can stop using prohibited concomitant drugs (β2 adrenoceptor agonists, anticholinergics, oral bronchodilators, antihistamines, leukotriene receptor antagonists) within the specified period before airway allergic examination;

Healthy subjects:

• 6 Body mass index (BMI) = weight (kg)/height2 (m2), and body mass index is within the range of 18.5 ~ 27.0 (including the critical value).

Exclusion Criteria:

Patients with any of the following criteria will not be included in the trial:

• 1 Patients with a past history of allergy to this type of reagent;
• 2 Patients with a history of heart disease who are difficult to adapt to bronchial provocation test;
• 3 Patients who have undergone thoracic or abdominal surgery within 6 months before the trial;
• 4 Patients who have undergone surgery for intracranial, ophthalmic diseases, ear, nose and throat diseases, and respiratory diseases 6 months before the trial;
• 5 Complicated pneumothorax and other respiratory diseases or tuberculosis and other infectious diseases;
• 6 Patients with diseases that may be affected by the use of cholinergic drugs (epilepsy, bradycardia, coronary artery occlusion, vagal tension, thyroid disease, arrhythmia, peptic ulcer, urinary tract disorders, etc.);
• 7 Patients with a past history of drug dependence or alcohol dependence;
• 8 Previous severe circulatory system diseases, hepatobiliary system diseases, digestive tract diseases, urinary system diseases, kidney diseases, blood diseases, endocrine system diseases, immune system diseases, malignant tumors, etc.;
• 9 Patients who are using cholinase inhibitors (treatment of myasthenia gravis);
• 10 Patients with unexplained urticaria;
• 11 Pregnant and lactating women;
• 12 Subjects with dyspnea, wheezing, wheezing on the day of the trial;
• 13 Patients with myocardial infarction or stroke, combined with hypertension (systolic blood pressure > 200 mmHg, diastolic blood pressure > 100 mmHg);
• 14 Poor cooperation in basic pulmonary function tests, not in line with quality control;
• 15 Use of drugs that will affect airway systolic function and airway inflammation, thereby affecting airway reactivity and can not be discontinued before the test (bronchodilator drugs, glucocorticoids, anti-allergic drugs and triene receptor antagonists and others);
• 16 Current smokers, those who quit for less than one year at the time of screening, and those with a smoking history of more than 10 packs/year;
• 17 Abnormalities in physical examination, laboratory tests, vital signs and test-related tests are clinically significant (based on clinician judgment);
• 18 The investigators think that there are any unsuitable for inclusion;

Patients with asthma:

• 1 Hospitalized for asthma exacerbation within 12 weeks;
• 2 Patients with combined respiratory diseases (such as COPD, etc.) that may affect the efficacy and safety evaluation of the drug;

Healthy subjects:

• 1 Have used any drugs in 2 weeks;
• 2 Patients, immediate family members suffering from allergic diseases (allergic rhinitis, specific rhinitis, allergic conjunctivitis, chronic urticaria, food allergy, etc.);
• 3 Patients with upper respiratory tract infection, acute sinusitis and other infection-related symptoms or have received treatment in 6 weeks.